首页 > 最新文献

Acta gastro-enterologica Belgica最新文献

英文 中文
Signet ring cells in the gastrointestinal tract: not always what it seems. 胃肠道中的盾形环细胞:并非总是表里如一。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-01 DOI: 10.51821/87.3.12986
M Vanhooren, A Billiet, T Hendrickx, J Vancanneyt, R Bisschop, F Van Here, H Topal, G De Hertogh, X Sagaert, J Dekervel, G Rasschaert

We describe two cases of pseudo-signet ring cells in gastric biopsies of otherwise asymptomatic adult patients. One male patient was diagnosed during follow-up of a previous intestinal type gastric adenocarcinoma and underwent surgery before recognition of this non-malignant entity. He suffered from a secondary anastomotic stenosis requiring dilatation. A second male patient was spared from surgery thanks to timely recognition by the pathologist and is still declared cancer-free until today. This extremely rare nonmalignant mimicker of cancerous signet ring cells, as seen in diffuse type gastric cancer can potentially mislead the clinician. The absence of any endoscopic abnormality should prompt a revision by an experienced pathologist, digestive oncologist and surgeon to avoid unnecessary interventions and morbidity.

我们描述了两例在无症状的成年患者胃活检中发现假肉芽肿环细胞的病例。其中一名男性患者是在对先前的肠型胃腺癌进行随访时被确诊的,并在发现这种非恶性实体之前接受了手术。他患有继发性吻合口狭窄,需要进行扩张手术。第二名男性患者由于病理学家的及时发现而免于手术,至今仍被宣布为无癌。这种在弥漫型胃癌中极为罕见的非恶性标志环细胞癌变模拟物可能会误导临床医生。如果内镜下没有任何异常,就应该由经验丰富的病理学家、消化系统肿瘤学家和外科医生进行复查,以避免不必要的干预和发病。
{"title":"Signet ring cells in the gastrointestinal tract: not always what it seems.","authors":"M Vanhooren, A Billiet, T Hendrickx, J Vancanneyt, R Bisschop, F Van Here, H Topal, G De Hertogh, X Sagaert, J Dekervel, G Rasschaert","doi":"10.51821/87.3.12986","DOIUrl":"https://doi.org/10.51821/87.3.12986","url":null,"abstract":"<p><p>We describe two cases of pseudo-signet ring cells in gastric biopsies of otherwise asymptomatic adult patients. One male patient was diagnosed during follow-up of a previous intestinal type gastric adenocarcinoma and underwent surgery before recognition of this non-malignant entity. He suffered from a secondary anastomotic stenosis requiring dilatation. A second male patient was spared from surgery thanks to timely recognition by the pathologist and is still declared cancer-free until today. This extremely rare nonmalignant mimicker of cancerous signet ring cells, as seen in diffuse type gastric cancer can potentially mislead the clinician. The absence of any endoscopic abnormality should prompt a revision by an experienced pathologist, digestive oncologist and surgeon to avoid unnecessary interventions and morbidity.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 3","pages":"418-420"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142455750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statin therapy: improving survival in patients with hepatocellular carcinoma and portal hypertension is possible? 他汀类药物治疗:改善肝细胞癌和门静脉高压症患者的生存率可行吗?
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-01 DOI: 10.51821/87.3.13018
G Dispinzieri, C Becchetti, C Mazzarelli, A Airoldi, F Aprile, L Cesarini, M Cucco, G Perricone, R Stigliano, M Vangeli, R Viganò, L S Belli

Statins are generally known for their lipid-lowering properties and protection against cardiovascular events. However, growing evidence suggests that statins are a promising treatment for patients with chronic liver disease. Specifically, there is data supporting their role in reducing portal pressure and having a chemopreventive effect on hepatocellular carcinoma (HCC). Treatment options for HCC remain limited with portal hypertension (PH), thus statins could represent an inexpensive alternative, increasing survival of patients with HCC and PH. These drugs cannot be considered standard of care without a cardiac-metabolic indication to prescription in this patient group, although the potential beneficial effect should be indication for prompt use whenever considered appropriate. Our aim is to review the effects of statins on PH and on HCC, both in the pre-clinical and clinical setting in literature, discussing safety issues and limitations to the current body of evidence.

他汀类药物因其降血脂和防止心血管事件而广为人知。然而,越来越多的证据表明,他汀类药物对慢性肝病患者的治疗大有可为。特别是,有数据支持他汀类药物在降低门脉压力和对肝细胞癌(HCC)具有化学预防作用方面的作用。门静脉高压症(PH)患者的治疗方案仍然有限,因此他汀类药物可能是一种廉价的替代疗法,可提高 HCC 和 PH 患者的生存率。在没有心脏代谢指征的情况下,这些药物不能被视为此类患者的标准治疗处方,但只要认为合适,这些药物的潜在疗效应成为及时使用的指征。我们的目的是回顾他汀类药物在临床前和临床文献中对 PH 和 HCC 的影响,讨论安全性问题和现有证据的局限性。
{"title":"Statin therapy: improving survival in patients with hepatocellular carcinoma and portal hypertension is possible?","authors":"G Dispinzieri, C Becchetti, C Mazzarelli, A Airoldi, F Aprile, L Cesarini, M Cucco, G Perricone, R Stigliano, M Vangeli, R Viganò, L S Belli","doi":"10.51821/87.3.13018","DOIUrl":"https://doi.org/10.51821/87.3.13018","url":null,"abstract":"<p><p>Statins are generally known for their lipid-lowering properties and protection against cardiovascular events. However, growing evidence suggests that statins are a promising treatment for patients with chronic liver disease. Specifically, there is data supporting their role in reducing portal pressure and having a chemopreventive effect on hepatocellular carcinoma (HCC). Treatment options for HCC remain limited with portal hypertension (PH), thus statins could represent an inexpensive alternative, increasing survival of patients with HCC and PH. These drugs cannot be considered standard of care without a cardiac-metabolic indication to prescription in this patient group, although the potential beneficial effect should be indication for prompt use whenever considered appropriate. Our aim is to review the effects of statins on PH and on HCC, both in the pre-clinical and clinical setting in literature, discussing safety issues and limitations to the current body of evidence.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 3","pages":"395-402"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142455752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isolated intestinal manifestation of an invasive varicella zoster virus reactivation in an immunocompromised patient: a case report. 一名免疫力低下患者的侵袭性水痘带状疱疹病毒再激活的孤立肠道表现:病例报告。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-01 DOI: 10.51821/87.3.11221
M Maly, G Coppens

Invasive varicella zoster infection is a rare but severe infectious disease, potentially affecting almost every organ system and presenting with a variety of symptoms. It is usually seen in immunocompromised patients, but also occurs in immunocompetent patients. Isolated intestinal manifestations without skin lesions are even more scarce. We present a case of a 78-year old immunocompromised man with an isolated intestinal Varicella Zoster reactivation. If not early diagnosed and treated, an invasive infection can lead to life-threatening complications. Therefore, awareness in both immunocompromised as immunocompetent patients is very important in the daily clinical practice.

侵袭性水痘带状疱疹感染是一种罕见但严重的传染病,可能影响几乎所有器官系统,并表现出各种症状。它通常见于免疫力低下的患者,但也会发生在免疫力正常的患者身上。无皮肤损害的孤立肠道表现则更为罕见。我们报告了一例 78 岁免疫功能低下的男性患者的孤立性肠道水痘带状疱疹再活化病例。如果不及早诊断和治疗,侵袭性感染可导致危及生命的并发症。因此,在日常临床实践中,对免疫力低下和免疫力正常的患者都要提高警惕。
{"title":"Isolated intestinal manifestation of an invasive varicella zoster virus reactivation in an immunocompromised patient: a case report.","authors":"M Maly, G Coppens","doi":"10.51821/87.3.11221","DOIUrl":"https://doi.org/10.51821/87.3.11221","url":null,"abstract":"<p><p>Invasive varicella zoster infection is a rare but severe infectious disease, potentially affecting almost every organ system and presenting with a variety of symptoms. It is usually seen in immunocompromised patients, but also occurs in immunocompetent patients. Isolated intestinal manifestations without skin lesions are even more scarce. We present a case of a 78-year old immunocompromised man with an isolated intestinal Varicella Zoster reactivation. If not early diagnosed and treated, an invasive infection can lead to life-threatening complications. Therefore, awareness in both immunocompromised as immunocompetent patients is very important in the daily clinical practice.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 3","pages":"421-423"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142455744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Need to treat? 需要治疗吗?
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-01 DOI: 10.51821/87.3.12234
L Lanneer, J Flamaing, P Roelandt
{"title":"Need to treat?","authors":"L Lanneer, J Flamaing, P Roelandt","doi":"10.51821/87.3.12234","DOIUrl":"https://doi.org/10.51821/87.3.12234","url":null,"abstract":"","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 3","pages":"435"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142455745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Noninvasive evaluation of significant liver fibrosis in chronic hepatitis B patients. 对慢性乙型肝炎患者明显肝纤维化的无创评估。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-01 DOI: 10.51821/87.3.13290
K H Dilcan, H T Gozdas

Background & aims: Chronic hepatitis B is still a major cause of morbidity and mortality worldwide. In recent years, there has been increasing research on inexpensive, noninvasive, reproducible methods for detecting fibrosis in the liver. In this study, we examined the efficacy of 15 different noninvasive fibrosis markers for predicting significant liver fibrosis in chronic hepatitis B patients.

Methods: Patients who underwent liver biopsy for chronic hepatitis B between 01.01.2010 and 01.01.2022 were retrospectively analysed. The study population was divided into two groups according to significant fibrosis (F≥3). Receiver operating characteristic analysis was performed to examine the diagnostic performance of these noninvasive fibrosis markers for the prediction of significant fibrosis. Multiple logistic regression analysis was used create a model which predicts significant fibrosis better than the individual markers.

Results: In total, 234 chronic hepatitis B patients were enrolled in this study. Among the 15 noninvasive fibrosis markers, King's score was found to have the biggest AUC in predicting significant fibrosis (F≥3). Furthermore, a model containing King's score, GUCI and GPR has the ability of prediction of significant fibrosis better than every individual marker (cut-off of the model >0,3356, p<0.0001).

Conclusion: According to our study results, the model containing King's score, GUCI and GPR can be used to predict significant liver fibrosis in chronic hepatitis B patients followed-up in countries with limited sources.

背景与目的:慢性乙型肝炎仍然是全球发病和死亡的主要原因。近年来,有关检测肝纤维化的廉价、无创、可重复方法的研究日益增多。在这项研究中,我们检测了 15 种不同的无创肝纤维化标志物对预测慢性乙型肝炎患者肝纤维化的有效性:回顾性分析了 2010 年 1 月 1 日至 2022 年 1 月 1 日期间接受肝活检的慢性乙型肝炎患者。根据肝纤维化程度(F≥3)将研究对象分为两组。研究人员对这些非侵入性纤维化标志物进行了接收者操作特征分析,以检验它们在预测明显纤维化方面的诊断性能。采用多元逻辑回归分析建立了一个模型,该模型比单个标记物更能预测明显的肝纤维化:本研究共招募了 234 名慢性乙型肝炎患者。在 15 个非侵入性纤维化指标中,King's 评分在预测明显纤维化方面具有最大的 AUC 值(F≥3)。此外,包含 King's 评分、GUCI 和 GPR 的模型预测显著纤维化的能力优于每个单独的标记物(模型的临界值大于 0,3356, p结论:根据我们的研究结果,包含 King 评分、GUCI 和 GPR 的模型可用于预测在资源有限的国家随访的慢性乙型肝炎患者的明显肝纤维化。
{"title":"Noninvasive evaluation of significant liver fibrosis in chronic hepatitis B patients.","authors":"K H Dilcan, H T Gozdas","doi":"10.51821/87.3.13290","DOIUrl":"https://doi.org/10.51821/87.3.13290","url":null,"abstract":"<p><strong>Background & aims: </strong>Chronic hepatitis B is still a major cause of morbidity and mortality worldwide. In recent years, there has been increasing research on inexpensive, noninvasive, reproducible methods for detecting fibrosis in the liver. In this study, we examined the efficacy of 15 different noninvasive fibrosis markers for predicting significant liver fibrosis in chronic hepatitis B patients.</p><p><strong>Methods: </strong>Patients who underwent liver biopsy for chronic hepatitis B between 01.01.2010 and 01.01.2022 were retrospectively analysed. The study population was divided into two groups according to significant fibrosis (F≥3). Receiver operating characteristic analysis was performed to examine the diagnostic performance of these noninvasive fibrosis markers for the prediction of significant fibrosis. Multiple logistic regression analysis was used create a model which predicts significant fibrosis better than the individual markers.</p><p><strong>Results: </strong>In total, 234 chronic hepatitis B patients were enrolled in this study. Among the 15 noninvasive fibrosis markers, King's score was found to have the biggest AUC in predicting significant fibrosis (F≥3). Furthermore, a model containing King's score, GUCI and GPR has the ability of prediction of significant fibrosis better than every individual marker (cut-off of the model >0,3356, p<0.0001).</p><p><strong>Conclusion: </strong>According to our study results, the model containing King's score, GUCI and GPR can be used to predict significant liver fibrosis in chronic hepatitis B patients followed-up in countries with limited sources.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 3","pages":"388-392"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142455747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of patients with positive anti-mitochondiral antibody and normal alkaline phosphatase levels for primary biliary cholangitis. 评估抗线粒体抗体阳性且碱性磷酸酶水平正常的原发性胆汁性胆管炎患者。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-01 DOI: 10.51821/87.2.12041
Halil Ibrahim Ellez, Nilay Danis, Ulus Salih Akarca

Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease typically diagnosed by elevated cholestatic liver enzymes and a positive anti-mitochondrial antibody (AMA) test. The clinical importance of AMA positivity in patients with normal cholestatic liver enzymes is unclear. The aim of this study was to determine the relationship between PBC and AMA positivity detected in individuals with normal cholestatic enzyme levels. The files of patients with AMA and/or AMA-M2 positivity between 2009 and 2018 and whose alkaline phosphatase (ALP) levels were below upper limit of normal (ULN) at initial admission were retrospectively analyzed. The ALP levels were normal in all patients. All patients had AMA positivity demonstrated by indirect immunofluorescence (IIF) or AMA-M2 positivity demonstrated by ELISA. A total of 16 patients underwent liver biopsy and seven (43.75%) showed changes consistent with those with PBC. A total of 12 patients were diagnosed with PBC and were treated and followed up with this diagnosis. People with AMA positivity and normal cholestasis enzyme levels are closely associated with PBC. Some of these patients were diagnosed with PBC as a result of biopsy and some were diagnosed by clinical and laboratory findings during follow-up.. The patients with an AMA titration of 1/20 were not associated with PBC. In our study, results similar to the studies confirmed by biopsies were obtained. In this regard, there is a need for prospective and retrospective studies with longer follow-up periods.

原发性胆汁性胆管炎(PBC)是一种慢性胆汁淤积性肝病,通常通过胆汁淤积性肝酶升高和抗线粒体抗体(AMA)检测阳性来诊断。在胆汁淤积性肝酶正常的患者中,AMA 阳性的临床重要性尚不明确。本研究旨在确定 PBC 与胆汁淤积性肝酶水平正常的患者中检测到的抗线粒体抗体阳性之间的关系。研究人员回顾性分析了2009年至2018年期间AMA和/或AMA-M2阳性且入院时碱性磷酸酶(ALP)水平低于正常上限(ULN)的患者档案。所有患者的ALP水平均正常。所有患者均通过间接免疫荧光(IIF)检测出 AMA 阳性,或通过酶联免疫吸附(ELISA)检测出 AMA-M2 阳性。共有 16 名患者接受了肝活检,其中 7 人(43.75%)的病变与 PBC 一致。共有 12 名患者被诊断为 PBC,并接受了治疗和随访。AMA 阳性且胆汁淤积酶水平正常的人与 PBC 关系密切。其中一些患者是通过活组织切片检查确诊为 PBC 的,另一些则是在随访过程中通过临床和实验室检查结果确诊的。AMA 滴定值为 1/20 的患者与 PBC 无关。在我们的研究中,得到的结果与通过活检确认的研究结果相似。在这方面,需要进行随访时间更长的前瞻性和回顾性研究。
{"title":"Evaluation of patients with positive anti-mitochondiral antibody and normal alkaline phosphatase levels for primary biliary cholangitis.","authors":"Halil Ibrahim Ellez, Nilay Danis, Ulus Salih Akarca","doi":"10.51821/87.2.12041","DOIUrl":"https://doi.org/10.51821/87.2.12041","url":null,"abstract":"<p><p>Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease typically diagnosed by elevated cholestatic liver enzymes and a positive anti-mitochondrial antibody (AMA) test. The clinical importance of AMA positivity in patients with normal cholestatic liver enzymes is unclear. The aim of this study was to determine the relationship between PBC and AMA positivity detected in individuals with normal cholestatic enzyme levels. The files of patients with AMA and/or AMA-M2 positivity between 2009 and 2018 and whose alkaline phosphatase (ALP) levels were below upper limit of normal (ULN) at initial admission were retrospectively analyzed. The ALP levels were normal in all patients. All patients had AMA positivity demonstrated by indirect immunofluorescence (IIF) or AMA-M2 positivity demonstrated by ELISA. A total of 16 patients underwent liver biopsy and seven (43.75%) showed changes consistent with those with PBC. A total of 12 patients were diagnosed with PBC and were treated and followed up with this diagnosis. People with AMA positivity and normal cholestasis enzyme levels are closely associated with PBC. Some of these patients were diagnosed with PBC as a result of biopsy and some were diagnosed by clinical and laboratory findings during follow-up.. The patients with an AMA titration of 1/20 were not associated with PBC. In our study, results similar to the studies confirmed by biopsies were obtained. In this regard, there is a need for prospective and retrospective studies with longer follow-up periods.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 2","pages":"282-286"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-calorie refeeding in adolescents with anorexia nervosa: a narrative review. 神经性厌食症青少年的高热量再喂养:叙述性综述。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-01 DOI: 10.51821/87.2.12851
C Roman, R Aglave, S Farine, C Joris, L Lefebvre, F Vermeulen

Background and objectives: Recent studies about refeeding in anorexia nervosa (AN) suggest starting with a high calorie diet. This narrative review aims to understand the initial refeeding management in hospitalized children and adolescents with AN and to develop a practical protocol.

Methods: We performed a comprehensive database search in June 2023 for abstracts published between January 2010 and May 2023 in different databases: Pubmed, The Cochrane Library and Embase with the terms refeeding syndrome, energy intake, diet therapy, weight restoration, hypophosphatemia, nutritional rehabilitation, anorexia nervosa, restrictive eating disorders, child, adolescent and young adult.

Results: Fifteen papers were included in this review. Twelve studies were retrospective or observational. Only 3 randomized controlled trials were found. Initial energy intake varies within a wide range between 500 and 2800 kcal per day but generally begins with higher calories than current recommendations. Only hypophosphatemia was often described without clinical refeeding syndrome. Initial weight restoration was better with high calorie refeeding (HCR). Length of stay was shorter with HCR in some studies. Long term outcomes were unknown. Only two studied severely malnourished patients (< 70 % mBMI).

Conclusion: In adolescents with AN and with a low risk of RS, high calorie refeeding is possible under close medical monitoring and with prompt electrolyte correction. Robust studies with a unified protocol are needed to confirm the safety of high calorie refeeding especially in severely malnourished adolescents with AN.

背景和目的:有关神经性厌食症(AN)患者再喂食的最新研究建议从高热量饮食开始。本综述旨在了解住院儿童和青少年厌食症患者的初始再喂养管理,并制定实用的方案:我们于 2023 年 6 月对 2010 年 1 月至 2023 年 5 月期间在不同数据库中发表的摘要进行了全面的数据库检索:方法:我们于 2023 年 6 月在不同的数据库中对 2010 年 1 月至 2023 年 5 月间发表的摘要进行了全面的数据库检索:Pubmed、The Cochrane Library 和 Embase,检索词包括反哺综合征、能量摄入、饮食疗法、体重恢复、低磷血症、营养康复、神经性厌食症、限制性进食障碍、儿童、青少年和年轻成人:本综述共收录了 15 篇论文。其中 12 篇为回顾性或观察性研究。仅发现 3 项随机对照试验。初始能量摄入量在每天 500 千卡到 2800 千卡之间的很大范围内变化,但开始摄入的热量通常高于当前建议的热量。通常只有低磷酸盐血症,没有临床反哺综合症。高热量进食(HCR)能更好地恢复初始体重。在一些研究中,HCR 的住院时间更短。长期结果尚不清楚。只有两项研究对严重营养不良的患者(体重指数低于 70%)进行了研究:结论:对于患有AN且RS风险较低的青少年,可以在严密的医疗监控下进行高热量再喂养,并及时纠正电解质。需要通过统一方案的有力研究来确认高热量再喂养的安全性,尤其是对严重营养不良的AN青少年。
{"title":"High-calorie refeeding in adolescents with anorexia nervosa: a narrative review.","authors":"C Roman, R Aglave, S Farine, C Joris, L Lefebvre, F Vermeulen","doi":"10.51821/87.2.12851","DOIUrl":"https://doi.org/10.51821/87.2.12851","url":null,"abstract":"<p><strong>Background and objectives: </strong>Recent studies about refeeding in anorexia nervosa (AN) suggest starting with a high calorie diet. This narrative review aims to understand the initial refeeding management in hospitalized children and adolescents with AN and to develop a practical protocol.</p><p><strong>Methods: </strong>We performed a comprehensive database search in June 2023 for abstracts published between January 2010 and May 2023 in different databases: Pubmed, The Cochrane Library and Embase with the terms refeeding syndrome, energy intake, diet therapy, weight restoration, hypophosphatemia, nutritional rehabilitation, anorexia nervosa, restrictive eating disorders, child, adolescent and young adult.</p><p><strong>Results: </strong>Fifteen papers were included in this review. Twelve studies were retrospective or observational. Only 3 randomized controlled trials were found. Initial energy intake varies within a wide range between 500 and 2800 kcal per day but generally begins with higher calories than current recommendations. Only hypophosphatemia was often described without clinical refeeding syndrome. Initial weight restoration was better with high calorie refeeding (HCR). Length of stay was shorter with HCR in some studies. Long term outcomes were unknown. Only two studied severely malnourished patients (< 70 % mBMI).</p><p><strong>Conclusion: </strong>In adolescents with AN and with a low risk of RS, high calorie refeeding is possible under close medical monitoring and with prompt electrolyte correction. Robust studies with a unified protocol are needed to confirm the safety of high calorie refeeding especially in severely malnourished adolescents with AN.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 2","pages":"287-293"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of psychotherapeutic approaches in treatment of functional dyspepsia, systematic review, and meta-analysis. 心理治疗方法在功能性消化不良治疗中的作用、系统回顾和荟萃分析。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-01 DOI: 10.51821/87.2.13044
W Zhang, Y Shen, J Hao, Y Zhao

Background: Functional dyspepsia is a common functional gastrointestinal disorder that is often challenging to treat. Psychotherapeutic interventions have been proposed as an alternative or adjunctive approach to conventional treatments, but their efficacy remains unclear.

Objective: This systematic review and meta-analysis aimed to evaluate the efficacy of psychotherapeutic interventions in the treatment of functional dyspepsia.

Methods: A comprehensive search of electronic databases was conducted, from inception to March 2023, for randomized controlled trials (RCTs) that evaluated the effects of psychotherapeutic interventions on patients with functional dyspepsia. The primary outcome measures were gastrointestinal symptoms, quality of life, depression, and anxiety. Data were extracted and analyzed using Review Manager 5.3 software. The risk of bias of the included studies was assessed using the Cochrane Risk of Bias tool.

Results: Sixteen RCTs comprising 1550 patients with functional dyspepsia were included in the meta-analysis. The types of psychotherapeutic interventions used in the included studies were cognitive-behavioral therapy (CBT), hypnotherapy, and mindfulness-based stress reduction (MBSR). The control groups were usual care, placebo, supportive therapy, or no treatment. The meta-analysis showed that psychotherapeutic interventions had a significant effect on reducing gastrointestinal symptoms,depression and anxiety in patients with functional dyspepsia. However, no significant improvement was observed in the quality-of-life scores of patients who received psychotherapeutic interventions compared to those in the control group.

Conclusion: Psychotherapeutic interventions, such as CBT, hypnotherapy, and MBSR, could be a useful adjunct to conventional treatments for functional dyspepsia, as they were found to significantly reduce gastrointestinal symptoms and anxiety in patients. However, further studies are needed to assess the long-term effects and generalizability of these interventions.

背景:功能性消化不良是一种常见的功能性胃肠道疾病,治疗起来往往具有挑战性。心理治疗干预已被提出作为常规治疗的替代或辅助方法,但其疗效仍不明确:本系统综述和荟萃分析旨在评估心理治疗干预在治疗功能性消化不良方面的疗效:方法:我们对电子数据库进行了全面检索,检索时间从开始到 2023 年 3 月,检索对象为评估心理治疗干预对功能性消化不良患者影响的随机对照试验 (RCT)。主要结果指标为胃肠道症状、生活质量、抑郁和焦虑。数据采用 Review Manager 5.3 软件进行提取和分析。使用 Cochrane 偏倚风险工具评估了纳入研究的偏倚风险:荟萃分析共纳入了16项研究,包括1550名功能性消化不良患者。纳入研究的心理治疗干预类型包括认知行为疗法(CBT)、催眠疗法和正念减压疗法(MBSR)。对照组为常规护理、安慰剂、支持疗法或无治疗。荟萃分析表明,心理治疗干预对减轻功能性消化不良患者的胃肠道症状、抑郁和焦虑有显著效果。然而,与对照组相比,接受心理治疗干预的患者的生活质量评分没有明显改善:心理治疗干预(如 CBT、催眠疗法和 MBSR)可作为功能性消化不良常规治疗的有效辅助手段,因为研究发现它们能显著减轻患者的胃肠道症状和焦虑。然而,还需要进一步的研究来评估这些干预措施的长期效果和可推广性。
{"title":"The role of psychotherapeutic approaches in treatment of functional dyspepsia, systematic review, and meta-analysis.","authors":"W Zhang, Y Shen, J Hao, Y Zhao","doi":"10.51821/87.2.13044","DOIUrl":"10.51821/87.2.13044","url":null,"abstract":"<p><strong>Background: </strong>Functional dyspepsia is a common functional gastrointestinal disorder that is often challenging to treat. Psychotherapeutic interventions have been proposed as an alternative or adjunctive approach to conventional treatments, but their efficacy remains unclear.</p><p><strong>Objective: </strong>This systematic review and meta-analysis aimed to evaluate the efficacy of psychotherapeutic interventions in the treatment of functional dyspepsia.</p><p><strong>Methods: </strong>A comprehensive search of electronic databases was conducted, from inception to March 2023, for randomized controlled trials (RCTs) that evaluated the effects of psychotherapeutic interventions on patients with functional dyspepsia. The primary outcome measures were gastrointestinal symptoms, quality of life, depression, and anxiety. Data were extracted and analyzed using Review Manager 5.3 software. The risk of bias of the included studies was assessed using the Cochrane Risk of Bias tool.</p><p><strong>Results: </strong>Sixteen RCTs comprising 1550 patients with functional dyspepsia were included in the meta-analysis. The types of psychotherapeutic interventions used in the included studies were cognitive-behavioral therapy (CBT), hypnotherapy, and mindfulness-based stress reduction (MBSR). The control groups were usual care, placebo, supportive therapy, or no treatment. The meta-analysis showed that psychotherapeutic interventions had a significant effect on reducing gastrointestinal symptoms,depression and anxiety in patients with functional dyspepsia. However, no significant improvement was observed in the quality-of-life scores of patients who received psychotherapeutic interventions compared to those in the control group.</p><p><strong>Conclusion: </strong>Psychotherapeutic interventions, such as CBT, hypnotherapy, and MBSR, could be a useful adjunct to conventional treatments for functional dyspepsia, as they were found to significantly reduce gastrointestinal symptoms and anxiety in patients. However, further studies are needed to assess the long-term effects and generalizability of these interventions.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 2","pages":"294-303"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Belgian consensus guideline on the management of anal fissures. 比利时肛裂治疗共识指南。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-01 DOI: 10.51821/87.2.11787
P Roelandt, G Bislenghi, G Coremans, D De Looze, M A Denis, H De Schepper, P Dewint, J Geldof, I Gijsen, N Komen, H Ruymbeke, J Stijns, M Surmont, D Van de Putte, S Van den Broeck, B Van Geluwe, J Wyndaele

Introduction: Acute and chronic anal fissures are common proctological problems that lead to relatively high morbidity and frequent contacts with health care professionals. Multiple treatment options, both topical and surgical, are available, therefore evidence-based guidance is preferred.

Methods: A Delphi consensus process was used to review the literature and create relevant statements on the treatment of anal fissures. These statements were discussed and modulated until sufficient agreement was reached. These guidelines were based on the published literature up to January 2023.

Results: Anal fissures occur equally in both sexes, mostly between the second and fourth decades of life. Diagnosis can be made based on cardinal symptoms and clinical examination. In case of insufficient relief with conservative treatment options, pharmacological sphincter relaxation is preferred. After 6-8 weeks of topical treatment, surgical options can be explored. Both lateral internal sphincterotomy as well as fissurectomy are well-established surgical techniques, both with specific benefits and risks.

Conclusions: The current guidelines for the management of anal fissures include recommendations for the clinical evaluation of anal fissures, and their conservative, topical and surgical management.

导言:急性和慢性肛裂是常见的肛肠病,发病率相对较高,患者需要频繁接触医护人员。目前有多种治疗方法可供选择,包括局部治疗和手术治疗,因此循证指导是首选:方法:采用德尔菲共识法对文献进行了审查,并制定了肛裂治疗的相关声明。这些声明经过讨论和修改,直到达成充分一致。这些指南基于截至 2023 年 1 月已发表的文献:肛裂在男女两性中的发病率相同,大多发生在生命的第二至第四个十年之间。可根据主要症状和临床检查进行诊断。如果保守治疗效果不佳,首选药物括约肌松弛术。局部治疗 6-8 周后,可考虑手术治疗。外侧内括约肌切开术和肛裂切除术都是成熟的外科技术,两者都有特定的优点和风险:目前的肛裂治疗指南包括对肛裂的临床评估、保守治疗、局部治疗和手术治疗的建议。
{"title":"Belgian consensus guideline on the management of anal fissures.","authors":"P Roelandt, G Bislenghi, G Coremans, D De Looze, M A Denis, H De Schepper, P Dewint, J Geldof, I Gijsen, N Komen, H Ruymbeke, J Stijns, M Surmont, D Van de Putte, S Van den Broeck, B Van Geluwe, J Wyndaele","doi":"10.51821/87.2.11787","DOIUrl":"10.51821/87.2.11787","url":null,"abstract":"<p><strong>Introduction: </strong>Acute and chronic anal fissures are common proctological problems that lead to relatively high morbidity and frequent contacts with health care professionals. Multiple treatment options, both topical and surgical, are available, therefore evidence-based guidance is preferred.</p><p><strong>Methods: </strong>A Delphi consensus process was used to review the literature and create relevant statements on the treatment of anal fissures. These statements were discussed and modulated until sufficient agreement was reached. These guidelines were based on the published literature up to January 2023.</p><p><strong>Results: </strong>Anal fissures occur equally in both sexes, mostly between the second and fourth decades of life. Diagnosis can be made based on cardinal symptoms and clinical examination. In case of insufficient relief with conservative treatment options, pharmacological sphincter relaxation is preferred. After 6-8 weeks of topical treatment, surgical options can be explored. Both lateral internal sphincterotomy as well as fissurectomy are well-established surgical techniques, both with specific benefits and risks.</p><p><strong>Conclusions: </strong>The current guidelines for the management of anal fissures include recommendations for the clinical evaluation of anal fissures, and their conservative, topical and surgical management.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 2","pages":"304-321"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Continued PPI use and gastrointestinal evaluations after a negative pH study in patients with throat symptoms from possible extraesophageal GERD. 在对可能患有食管外胃食管反流病的咽喉症状患者进行 pH 值检测呈阴性后,继续使用 PPI 并进行胃肠道评估。
IF 1.3 4区 医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-01 DOI: 10.51821/87.2.12969
D L Cohen, V Richter, A Mari, H Shirin, A Bermont

Background: Recent guidelines have advocated for upfront pH testing in patients with isolated symptoms of extra-esophageal gastrointestinal reflux disease (EE-GERD) under the assumption that a negative pH study will prevent further gastrointestinal (GI) investigations, proton pump inhibitor (PPI) use, and reduce cost. We sought to evaluate if this actually occurs.

Methods: A retrospective study was performed on patients who underwent 24-hour combined pH-impedance testing off PPI for suspected EE-GERD. A negative study was defined as DeMeester score <14.7.

Results: 59 patients were included (mean age 53.2; 50.8% women). Most (38, 64.4%) had a negative study. Findings of laryngopharyngoreflux on laryngoscopy did not predict pH results. Those with a negative study had the same number of followup GI appointments, repeat endoscopies, and repeat pH studies compared to those with a positive study (p=NS). While PPIs were more frequently stopped in those with a negative pH study, still 14 (36.8%) were continued on a PPI. At the end of the follow-up period (mean 43.6 months), 18 (47.4%) subjects with a negative pH study were still prescribed PPIs. Patients who were diagnosed with post-nasal drip or rhinits were significantly less likely to still be receiving a PPI (5.6% vs 35.0%, p=0.045).

Conclusions: Despite a negative pH study, a substantial number of patients with isolated EE-GERD symptoms are continued on a PPI and they undergo GI follow-up at the same rate as those with a positive study. These findings bring into question the recent recommendations for upfront pH testing in suspected EE-GERD and its reported cost savings.

背景:最近的指南提倡对有食管外胃肠道反流病(EE-GERD)孤立症状的患者进行前期 pH 值检测,其假设是,阴性 pH 值检测可避免进一步的胃肠道(GI)检查、质子泵抑制剂(PPI)的使用并降低成本。我们试图评估这种情况是否确实存在:我们对疑似 EE 胃食管反流病的患者进行了一项回顾性研究,这些患者接受了 24 小时 pH- 阻抗联合检测,未使用 PPI。结果:共纳入 59 名患者(平均年龄 53 岁):共纳入 59 名患者(平均年龄 53.2 岁;50.8% 为女性)。大多数患者(38 人,64.4%)的研究结果为阴性。喉镜检查发现的喉咽反流并不能预测 pH 值结果。与pH值为阳性的患者相比,pH值为阴性的患者接受消化道复诊、重复内镜检查和重复pH值检查的次数相同(p=NS)。虽然 pH 值阴性者更常停用 PPI,但仍有 14 人(36.8%)继续服用 PPI。在随访期结束时(平均 43.6 个月),有 18 名(47.4%)pH 值阴性的受试者仍在服用 PPI。被诊断为鼻后滴流或鼻炎的患者继续服用 PPI 的可能性明显较低(5.6% vs 35.0%,P=0.045):结论:尽管pH值研究结果呈阴性,但仍有相当多的孤立性EE-胃食管反流症状患者继续服用PPI,而且他们接受消化道随访的比例与研究结果呈阳性的患者相同。这些研究结果使人们对最近提出的对疑似 EE-GERD 患者进行前期 pH 值检测的建议及其节约成本的报道产生了质疑。
{"title":"Continued PPI use and gastrointestinal evaluations after a negative pH study in patients with throat symptoms from possible extraesophageal GERD.","authors":"D L Cohen, V Richter, A Mari, H Shirin, A Bermont","doi":"10.51821/87.2.12969","DOIUrl":"https://doi.org/10.51821/87.2.12969","url":null,"abstract":"<p><strong>Background: </strong>Recent guidelines have advocated for upfront pH testing in patients with isolated symptoms of extra-esophageal gastrointestinal reflux disease (EE-GERD) under the assumption that a negative pH study will prevent further gastrointestinal (GI) investigations, proton pump inhibitor (PPI) use, and reduce cost. We sought to evaluate if this actually occurs.</p><p><strong>Methods: </strong>A retrospective study was performed on patients who underwent 24-hour combined pH-impedance testing off PPI for suspected EE-GERD. A negative study was defined as DeMeester score <14.7.</p><p><strong>Results: </strong>59 patients were included (mean age 53.2; 50.8% women). Most (38, 64.4%) had a negative study. Findings of laryngopharyngoreflux on laryngoscopy did not predict pH results. Those with a negative study had the same number of followup GI appointments, repeat endoscopies, and repeat pH studies compared to those with a positive study (p=NS). While PPIs were more frequently stopped in those with a negative pH study, still 14 (36.8%) were continued on a PPI. At the end of the follow-up period (mean 43.6 months), 18 (47.4%) subjects with a negative pH study were still prescribed PPIs. Patients who were diagnosed with post-nasal drip or rhinits were significantly less likely to still be receiving a PPI (5.6% vs 35.0%, p=0.045).</p><p><strong>Conclusions: </strong>Despite a negative pH study, a substantial number of patients with isolated EE-GERD symptoms are continued on a PPI and they undergo GI follow-up at the same rate as those with a positive study. These findings bring into question the recent recommendations for upfront pH testing in suspected EE-GERD and its reported cost savings.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 2","pages":"255-261"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta gastro-enterologica Belgica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1